Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Newton, Melissa J ^a   Hayes, Sandi C ^a   Janda, Monika ^a   Webb, Penelope M ^b   Obermair, Andreas ^c   Eakin, Elizabeth G ^d   Wyld, David ^c   Gordon, Louisa G ^e   Beesley, Vanessa L ^b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

Author keywords

Chemotherapy; Exercise; Feasibility; Ovarian neoplasm

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; EXERCISE; FEASIBILITY STUDY; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MULTIPLE CYCLE TREATMENT; NUTRITIONAL ASSESSMENT; OVARY CANCER; PATIENT ATTITUDE; PATIENT SAFETY; PERSONALIZED MEDICINE; PILOT STUDY; QUALITY OF LIFE; THERAPY EFFECT; TREATMENT DURATION; WALKING; WELLBEING; AGED; CLINICAL TRIAL; KINESIOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; EXERCISE THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PILOT PROJECTS; TREATMENT OUTCOME; WALKING;

EID: 80052581582     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-389     Document Type: Article

References (30)

1. Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR) Cancer in Australia 2000. 2003, Canberra: AIHW (Cancer Series no 23), AIHW Cat. No. CAN 18, Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR).
2. Quasthoff S, Hartung H. Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249:9-17. 10.1007/PL00007853, 11954874.
3. Gordon LG, Scuffham PA, Beesley VL, Green AC, DeFazio A, Wyld DK, Clavarino AM, Webb PM. Australian Ovarian Cancer Study Group Outcomes and related medical costs for women with ovarian cancer in Australia: a patient-level analysis over 21/2 years. Int J Gynecol Cancer 2010, 20:757-765. 10.1111/IGC.0b013e3181dbd13f, 20973265, Australian Ovarian Cancer Study Group.
4. Schwartz A. Physical activity after a cancer diagnosis: psychosocial outcomes. Cancer Invest 2004, 22(1):82-92. 10.1081/CNV-120027582, 15069765.
5. Olsen CM, Bain CJ, Jordan S, Nagle C, Green A, Whiteman D, Webb P, . Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group Recreational Physical Activity and Epithelial Ovarian Cancer: A Case-Control Study, Systematic Review, and Meta-analysis. Cancer Epidemiol Biomarkers Prev 2007, 16(11):2321-2330. 10.1158/1055-9965.EPI-07-0566, 18006921, Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group.
6. Bodurka-Bevers D, Basen-Engquist K, Carmack C, Fitzgerald M, Wolf J, de Moor C, Gershenson D. Depression, Anxiety, and Quality of Life in Patients with Epithelial Ovarian Cancer. Gynecol Oncol 2000, 78:302-308. 10.1006/gyno.2000.5908, 10985884.
7. Wenzel L, Huang H, Armstrong D, Walker J, Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:437-443. 10.1200/JCO.2006.07.3494, 17264340.
8. Oken MM, Creech RH, Tormey DC, Horton J, Davis T, McFadden ET, Carbone P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655. 10.1097/00000421-198212000-00014, 7165009.
9. Markman M, Bundy B, Alberts D, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19(4):1001-1007.
10. Armstrong DK, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L, Walker J, Burger R, . for the Gynecologic Oncology Group Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Eng J Med 2006, 354(1):34-43. 10.1056/NEJMoa052985, 16394300, for the Gynecologic Oncology Group.
11. Hirria A, Leung D, Trainor K, Borgen P, Norton L, Hudis C. Factor influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol 2003, 46:121-126. 10.1016/S1040-8428(02)00133-6, 12711357.
12. Law CC, Fu YT. Postoperative adjuvant 5-Fluororuacil plus levamisole chemotherapy for stage III colon carcinoma: 7-year experience in a single institution. J Hong Kong College Rad 2002, 5:97-104.
13. D'hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van Oosterom A. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drug 2004, 15:341-346.
14. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 2010, 4:87-100. 10.1007/s11764-009-0110-5, 20052559.
15. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid R, Friedenreich C, Ladha A, Proulx C, Vallance J, Lane K, Yasui Y, McKenzie D. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 2007, 25:4396-4404. 10.1200/JCO.2006.08.2024, 17785708.
16. Hayes SC, Spence RR, Galvao DA, Newton R. Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport 2009, 12:428-434. 10.1016/j.jsams.2009.03.002, 19428291.
17. Von Gruenigen V, Frasure H, Kavanagh M, Lerner E, Waggoner SE, Courneya KS. Feasibility of a lifestyle intervention for ovarian cancer patients receiving adjuvant chemotherapy. Gynecol Oncol 2011,
18. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
19. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67(6):361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
20. Chang V, Hwang S, Feuerman M, Kasimis B, Thaler H. The Memorial Symptom Assessment Scale Short Form (MSAS-SF) Validity and Reliability. Cancer 2000, 89:1162-1171. 10.1002/1097-0142(20000901)89:5<1162::AID-CNCR26>3.0.CO;2-Y, 10964347.
21. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald M, Webster K, Cella D, Hu S, Gershenson D. Reliability and validity of the functional assessment of cancer therapy - Ovarian. J Clin Oncol 2001, 19:1809-1817.
22. Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, Inoue E, Koh H, Nakane T, Takeoka Y, Ohsawa M, Koh KR, Yamane T, Nakao Y, Ohta K, Mugitani A, Teshima H, Hino M. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exper Clin Can Res 2009, 28:116.
23. Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J 2009, 39(8):495-501. 10.1111/j.1445-5994.2008.01880.x, 19732197.
24. Puhan M, Frey M, Büchi S, Schünemann H. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcome 2008, 6:46.
25. Walker P. Which symptoms are prevalent in patients with recurrent ovarian cancer?. J Clin Oncol 2008, 26(No 15S):20689.
26. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 2005, 58(12):1217-1219. 10.1016/j.jclinepi.2005.07.009, 16291464.
27. Queensland Centre for Gynecological Cancer. Outcome data statistical report 2008,
28. Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE, Handman M. The group psychotherapy and home-based physical exercise (Group-Hope) trail in cancer survivors: Physical fitness and quality of life outcomes. Psycho-oncology 2003, 12:357-374. 10.1002/pon.658, 12748973.
29. Stevinson C, Capstick V, Schepansky A, Tonkin K, Vallance JK, Ladha AB, Steed H, Faught W, Courneya KS. Physical activity preferences of ovarian cancer survivors. Psycho-oncology 2009, 18(4):422-428. 10.1002/pon.1396, 19243089.
30. Joly F, Vardy J, Pintilie M, Tannock I. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 2007, 18:1935-1942. 10.1093/annonc/mdm121, 17698837.